Subareolar Sclerosing Ductal Hyperplasia.

TitleSubareolar Sclerosing Ductal Hyperplasia.
Publication TypeJournal Article
Year of Publication2017
AuthorsCheng E, D'Alfonso TM, Arafah M, Rolon RMarrero, Ginter PS, Hoda SA
JournalInt J Surg Pathol
Volume25
Issue1
Pagination4-11
Date Published2017 Feb
ISSN1940-2465
KeywordsAdolescent, Adult, Aged, Aged, 80 and over, Breast Diseases, Breast Neoplasms, Carcinoma, Female, Humans, Hyperplasia, Middle Aged, Sclerosis, Young Adult
Abstract

Subareolar sclerosing duct hyperplasia (SSDH) remains to be fully characterized nearly 20 years after initial description. Thirty-five SSDH cases diagnosed over a 16-year period (January 2000 to December 2015) were reviewed. All patients were female (mean age = 59 years, range = 18-80) who had presented with a unilateral solitary lesion (left 22, right 13) with a mean size of 1.3 cm (range = 0.4-3.0 cm), and showed florid and papillary epithelial hyperplasia with dense sclerosis without involvement of nipple or areolar epidermis. Significant lesions concurrent within SSDH included low-grade adenosquamous carcinoma (n = 1), ductal carcinoma in situ (DCIS; n = 1), lobular carcinoma in situ (LCIS; n = 1), and atypical ductal hyperplasia (ADH; n = 13). No case of SSDH recurred in a mean follow-up of 44 months (range = 6-189). Subsequent significant lesions occurred in 6 patients: DCIS (n = 3; ipsilateral 2, contralateral 1), ipsilateral ADH (n = 2), and ipsilateral atypical lobular hyperplasia (n = 1). Long-term follow-up for patients with SSDH is indicated as DCIS can occur subsequently in either breast.

DOI10.1177/1066896916677288
Alternate JournalInt J Surg Pathol
PubMed ID27831531
Related Faculty: 
Syed Hoda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700